Qineng Si

Biotechnology Reseach Center, Cuixi Academy of Biotechnology, Zhuji, 311800, Zhejiang, China
Author    Correspondence author
International Journal of Molecular Veterinary Research, 2024, Vol. 14, No. 5   
Received: 02 Apr., 2024    Accepted: 18 May, 2024    Published: 13 Jun., 2025

This is an open access article published under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

This study studys the potential and limitations of various animal models used in immunotherapy research, with a focus on genetically engineered immunodeficient mice, patient-derived xenografts (PDXs), and humanized mouse models. These models are instrumental in understanding the interactions between the immune system and tumors, and in preclinical testing of new immunotherapeutic agents. However, significant challenges remain, including species-specific differences that limit the translational relevance of these models to human clinical outcomes. Advances in humanized mouse models, which incorporate human immune cells and tumor tissues, offer promising avenues for more accurate preclinical assessments. Despite their potential, these models also face limitations such as incomplete immune system reconstitution and high costs. This study highlights the need for continued refinement of animal models to enhance their predictive power and translational applicability in cancer immunotherapy research.

Animal models; Cancer immunotherapy; Humanized mice; Patient-Derived xenografts (PDXs); Preclinical studies